Compare LTRX & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LTRX | CRDF |
|---|---|---|
| Founded | 1989 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Communications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 225.9M | 187.9M |
| IPO Year | 2000 | N/A |
| Metric | LTRX | CRDF |
|---|---|---|
| Price | $6.89 | $2.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $6.17 | ★ $10.83 |
| AVG Volume (30 Days) | 584.8K | ★ 990.1K |
| Earning Date | 02-05-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $118,294,000.00 | $501,000.00 |
| Revenue This Year | $4.59 | N/A |
| Revenue Next Year | $12.82 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.91 | $1.90 |
| 52 Week High | $6.96 | $4.99 |
| Indicator | LTRX | CRDF |
|---|---|---|
| Relative Strength Index (RSI) | 72.98 | 55.24 |
| Support Level | $5.94 | $2.72 |
| Resistance Level | $6.63 | $3.31 |
| Average True Range (ATR) | 0.38 | 0.20 |
| MACD | 0.07 | -0.04 |
| Stochastic Oscillator | 98.07 | 41.40 |
Lantronix Inc is a networking company. It provides secure data access and management solutions for the Internet of Things (IoT) and information technology assets. It organizes its products and solutions into three product lines: Embedded IoT Solutions, IoT Systems Solutions, and Software and Services. The IoT System Solutions segment is the key revenue driver for the company. The company serves a diverse range of markets including healthcare, industrial, security, energy, transportation, and government networking. Its primary geographic markets are the Americas, Europe, the Middle East and Africa, and Asia Pacific Japan. The Americas contribute the vast majority of total revenue.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.